Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

5-HT1A/5-HT2C receptor ligands from Roche

April 5, 1996

New anthranilide in phase I at Glaxo Wellcome

April 5, 1996

L-745870: D4 antagonist for schizophrenia

April 5, 1996

New antipsychotic drug in phase I at P&U

April 5, 1996

New antipsychotic drugs from HMR

April 5, 1996

Meiji claims improved antipsychotic agents

April 5, 1996

Pherin develops vomeropherins for anxiety

April 5, 1996

Lilly's tachykinin antagonists for chronic pain

April 5, 1996

Solvay acquires betahistine rights

March 15, 1996

Alpha2-adrenoceptor antagonists with neuroprotective effects

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...